Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli
about
Methodology in improving antibiotic implementation policiesAntibiotic resistance in primary care in Austria - a systematic review of scientific and grey literatureAn update on the management of urinary tract infections in the era of antimicrobial resistance.Emergence of community-acquired extended-spectrum beta-lactamase Escherichia coli (ESBLEC) in Honolulu: a case series of three individuals with community-acquired ESBLEC bacteriuriaRelationship of biofilm formation and different virulence genes in uropathogenic Escherichia coli isolates from Northwest Iran.Molecular Basis of Acute Cystitis Reveals Susceptibility Genes and Immunotherapeutic Targets.Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.Adherence to Hospital Antibiotic Policy for Treatment of Escherichia coli ESBL in Urine.High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study.Determination of Extended-Spectrum β-Lactamases and AmpC Production in Uropathogenic Isolates of Escherichia coli and Susceptibility to Fosfomycin.Comparative Evaluation of Fosfomycin Activity with other Antimicrobial Agents against E.coli Isolates from Urinary Tract Infections.Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria.Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.Antibiotic Prescribing for Urinary Tract Infections in the Emergency Department Based on Local Antibiotic Resistance Patterns: Implications for Antimicrobial Stewardship.Nitrofurantoin safety and effectiveness in treating acute uncomplicated cystitis (AUC) in hospitalized adults with renal insufficiency: antibiotic stewardship implications.Susceptibility to β-lactams and quinolones of Enterobacteriaceae isolated from urinary tract infections in outpatients.Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production.Prophylactic efficacy of cephamycin plus fluoroquinolones in high risk patients on inhibiting infectious complications after transrectal prostate biopsy.Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: a review.Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy.Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea.High frequency of co-resistance in CTX-M-producing Escherichia coli to non-beta-lactam antibiotics, with the exceptions of amikacin, nitrofurantoin, colistin, tigecycline, and fosfomycin, in a county of Sweden.Impact of pH on activity of trimethoprim, fosfomycin, amikacin, colistin and ertapenem in human urine.Update in adult urinary tract infection.
P2860
Q26744801-31662BE7-0EF7-43F5-9962-25CDF1D53367Q26996633-2A0F96A1-8D71-4AA4-99C7-0201B2295D03Q30244815-6DFC31A3-8FA8-4D21-8BFF-B8438239DEB1Q35600060-683C6334-BBA4-41D8-B457-E956463E8174Q35881839-94DD3A81-0670-4010-BB76-B2DBF9257587Q36161576-0503BB8F-D19E-403A-AAF4-FDB55F977395Q36180580-A51EA367-33C8-4F69-9FC5-64B7927D1FFFQ36830992-75395DDC-DC25-412C-9F72-B55D8FF3DEB4Q37484304-17AA8D90-7709-4A9B-95CE-CEC9DEFFD9FEQ37544647-31A390B5-F900-4AC4-9737-B22F59434EF6Q37670556-BD1F09BB-2569-422A-9D99-A28DBC84B83BQ37734217-51FBEFFD-F987-4CB3-8C18-E35A89E3E06DQ38143651-F8583CEE-920A-401F-951E-BD1BE8A407B0Q38849466-0BA6F257-575C-49C4-A37D-4497C13F9938Q40274846-92210698-D190-4EE1-857E-D6EB7DE1AB1EQ40347749-4AFA5F53-2579-4EDE-9550-2E76AAA4D3FAQ40862248-52180E38-AD5C-4E43-A455-FE72319222CCQ40886408-EB1093A8-3E25-464D-A74D-D3AD363C55C5Q40967518-224FC316-3224-4E76-9C75-346170EC2DF0Q41099994-01450486-371D-45FB-8EC0-19C5DF110464Q41433212-D2FC3588-BB46-412F-80A6-6A6B7E036751Q48357061-91DED95B-B24A-469C-BB8A-051F65C0F580Q51445786-9AAB1535-E90B-4810-9FD2-8DB9F1C9E4F9Q54315149-BCD5DF38-0912-46BB-A917-A7B49ACC4ACCQ54324569-AAE3D9B0-B133-4965-9419-C2521DA9274EQ54326424-09781F85-A5D6-4FD6-B63B-7CD5E1AA272AQ54353642-46AAA297-7C59-4AC5-BB35-2BEFD2DE8CAD
P2860
Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Oral treatment options for amb ...... ase-producing Escherichia coli
@ast
Oral treatment options for amb ...... ase-producing Escherichia coli
@en
Oral treatment options for amb ...... ase-producing Escherichia coli
@nl
type
label
Oral treatment options for amb ...... ase-producing Escherichia coli
@ast
Oral treatment options for amb ...... ase-producing Escherichia coli
@en
Oral treatment options for amb ...... ase-producing Escherichia coli
@nl
prefLabel
Oral treatment options for amb ...... ase-producing Escherichia coli
@ast
Oral treatment options for amb ...... ase-producing Escherichia coli
@en
Oral treatment options for amb ...... ase-producing Escherichia coli
@nl
P2093
P2860
P356
P1476
Oral treatment options for amb ...... ase-producing Escherichia coli
@en
P2093
Alexandra Wojna
Markus Hell
Simon Auer
P2860
P304
P356
10.1128/AAC.01760-09
P407
P577
2010-06-28T00:00:00Z